187 related articles for article (PubMed ID: 20031628)
21. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
[TBL] [Abstract][Full Text] [Related]
22. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
[TBL] [Abstract][Full Text] [Related]
23. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
24. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Storey RF; Melissa Thornton S; Lawrance R; Husted S; Wickens M; Emanuelsson H; Cannon CP; Heptinstall S; Armstrong M
Platelets; 2009 Aug; 20(5):341-8. PubMed ID: 19637098
[TBL] [Abstract][Full Text] [Related]
26. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease.
Cavallari U; Trabetti E; Malerba G; Biscuola M; Girelli D; Olivieri O; Martinelli N; Angiolillo DJ; Corrocher R; Pignatti PF
BMC Med Genet; 2007 Sep; 8():59. PubMed ID: 17803810
[TBL] [Abstract][Full Text] [Related]
27. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
28. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
29. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Bañuelos C; Hernández-Antolín R; Escaned J; Moreno R; Alfonso F; Macaya C
Eur Heart J; 2004 Nov; 25(21):1903-10. PubMed ID: 15522469
[TBL] [Abstract][Full Text] [Related]
30. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
[TBL] [Abstract][Full Text] [Related]
31. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
32. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
[TBL] [Abstract][Full Text] [Related]
33. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Price MJ; Nayak KR; Barker CM; Kandzari DE; Teirstein PS
Am J Cardiol; 2009 May; 103(10):1339-43. PubMed ID: 19427425
[TBL] [Abstract][Full Text] [Related]
34. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
35. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
[TBL] [Abstract][Full Text] [Related]
36. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
[TBL] [Abstract][Full Text] [Related]
37. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
39. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
Hochholzer W; Trenk D; Frundi D; Neumann FJ
Thromb Res; 2007; 119(3):285-91. PubMed ID: 16603231
[TBL] [Abstract][Full Text] [Related]
40. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]